Effect of Intervention on Progesterone Levels Before Euploid Embryo Transfer in Pregnancy Outcomes.

NACompletedINTERVENTIONAL
Enrollment

598

Participants

Timeline

Start Date

November 15, 2018

Primary Completion Date

February 28, 2020

Study Completion Date

February 28, 2020

Conditions
InfertilityProgesteroneFrozen Embryo TransferEuploid Embryo TransferPregnancy OutcomeArtificial CycleOngoing Pregnancy
Interventions
DRUG

Low Progesterone

"Additional daily dosage of subcutaneous progesterone (Psc) 25 mg/day at night since D4 (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night) New Progesterone analysis on D5 before warming the embryo. Group 2a (Canceled Group, P on D5 \<10.64 ng/mL): cancel PGT-FET. Scheduling a new procedure under different P supplementation.~Group 2b (Restored Progesterone Group, P on D5 \>10.64 ng/mL): continue HRT as previously described (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night). Warming and transfer the same day (D5)~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"

DRUG

Normal Progesterone

"Same Progesterone supplementation (vaginal micronized P 200mg/200mg/200mg) Warming and transfer on D5~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"

Trial Locations (1)

08028

Departamento Ginecología, Obstetricia y Reproducción . Hospital Universitari Dexeus, Barcelona

All Listed Sponsors
collaborator

Fundación Santiago Dexeus Font

OTHER

collaborator

Dexeus Clinic Woman

OTHER

lead

Fundacion Dexeus

OTHER

NCT03740568 - Effect of Intervention on Progesterone Levels Before Euploid Embryo Transfer in Pregnancy Outcomes. | Biotech Hunter | Biotech Hunter